WTX 1011
Alternative Names: WTX-1011Latest Information Update: 29 Dec 2025
At a glance
- Originator Werewolf Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 18 Dec 2025 Werewolf Therapeutics announces intention to submit an Investigational New Drug application for Prostate cancer by min-2027
- 18 Dec 2025 Pharmacodynamics data from a preclinical study in Prostate cancer released by Werewolf Therapeutics
- 28 Aug 2025 WTX 1011 is available for licensing as of 28 Aug 2025. https://werewolftx.com/contact/